01—Abstract
Summary
Summary of the 10-Q filed December 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Veeva Systems Inc. filed this Form 10-Q for the quarter ended October 31, 2024.
For the three months ended October 31, 2024, total revenues were $699.2 milliona, up from $616.5 million, driven by subscription services revenue of $580.9 million (versus $494.9 million). Operating income was $181.4 million compared with $128.5 million a year earlier, and net income was $185.8 million, or $1.13 per diluted share, versus $135.2 million, or $0.83 per diluted share. For the nine months ended October 31, 2024, total revenues were $2.03 billion, net income was $518.5 million, and net cash provided by operating activities was $1.02 billion.
As of October 31, 2024, cash, cash equivalents and short-term investments totaled $5.1 billionb, and total stockholders' equity was $5.50 billion. Deferred revenue declined to $739.7 million from $1.05 billion at January 31, 2024, which the company attributes partly to the seasonality of annual billings. Management expects operating cash flow in the fourth quarter to be substantially lower and says cash tax payments tied to research and development expenditure capitalization will reduce operating cash flows in the fiscal year ending January 31, 2025.
The filing also details ongoing litigation with IQVIA, including trade secret claims and Veeva's antitrust counterclaims seeking damages exceeding $200 millionc. The company states it cannot estimate the outcome, and it expects the trial originally scheduled for February 10, 2025 not to begin on that date. A separate California non-compete matter has a trial date of June 16, 2025.
02—Key points
Key Highlights
- Total revenues for the three months ended October 31, 2024 were $699.2 million, up from $616.5 million, with subscription services revenue rising to $580.9 million.
- Operating income for the quarter was $181.4 million, compared with $128.5 million in the prior-year quarter; gross margin was 75% versus 73%.
- Net income for the quarter was $185.8 million, or $1.13 per diluted share, compared with $135.2 million, or $0.83 per diluted share.
- Net cash provided by operating activities for the nine months was $1.02 billion, up from $853.6 million, and management expects operating cash flow to be substantially lower in the fourth quarter.
- Cash, cash equivalents and short-term investments totaled $5.1 billion at October 31, 2024, against total liabilities of $951.5 million.
- Deferred revenue fell to $739.7 million from $1.05 billion at January 31, 2024, which management says is affected by billing seasonality and renewal timing.
- IQVIA litigation continues, with IQVIA's trade secret claims and Veeva's antitrust counterclaims seeking damages exceeding $200 million; the February 10, 2025 trial date is no longer expected to hold.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Veeva Systems kept $0.27.
- Revenue$699.2M100.0%
- Cost of revenue−$174.4M24.9%
- Gross profit$524.8M75.1%
- Operating costs−$343.5M49.1%
- Operating income$181.4M25.9%
- Interest, other & tax$4.5M0.6%
- Net income$185.8M26.6%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed December 9, 2024Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $699.21M$616.50M | +13.4% |
| Cost of Revenue | $174.39M$167.68M | +4.0% |
| Gross Profit | $524.82M$448.82M | +16.9% |
| R&D Expenses | $172.41M$161.28M | +6.9% |
| Operating Expenses | $343.46M$320.33M | +7.2% |
| Operating Income | $181.35M$128.49M | +41.1% |
| Net Income | $185.81M$135.16M | +37.5% |
| EPS (Basic) | $1.15$0.84 | +36.9% |
| EPS (Diluted) | $1.13$0.83 | +36.1% |
| Shares Outstanding (Basic) | 161.99M160.77M | +0.8% |
| Shares Outstanding (Diluted) | 164.98M163.76M | +0.7% |
05—Questions
Frequently Asked Questions
How did Veeva's revenue and profitability trend in the quarter?
Total revenues grew to $699.2 million from $616.5 million, and operating income rose to $181.4 million from $128.5 million. Net income increased to $185.8 million from $135.2 million, and diluted EPS rose to $1.13 from $0.83. The filing attributes subscription growth mainly to R&D Solutions ($59 million of the quarterly increase) and Commercial Solutions ($27 million).
Why did deferred revenue decline, and what does that mean for cash flow?
Deferred revenue decreased to $739.7 million from $1.05 billion at January 31, 2024. The company states that the first fiscal quarter is seasonally its strongest for cash collections from annual billings. Management expects operating cash flow to be substantially lower in the fourth quarter and says cash taxes related to research and development expenditure capitalization will reduce operating cash flow in the fiscal year ending January 31, 2025.
What is the status of the IQVIA litigation?
IQVIA alleges trade secret misappropriation, and Veeva has counterclaimed for antitrust violations seeking damages exceeding $200 million. Cross motions for summary judgment on the trade secret claims were filed in September 2024, and a hearing has been set. Veeva does not expect the trial to begin on February 10, 2025, as previously scheduled, and says it cannot estimate the amount or range of any gain or loss.
What drove the increase in stock-based compensation and operating expenses?
Stock-based compensation totaled $117.9 million for the quarter, up from $101.2 million. General and administrative expenses rose $10 million in the quarter, primarily due to stock-based compensation tied to the June 2024 equity grant to the Chief Executive Officer. The company expects general and administrative expenses to increase further in the near term because of that grant.
How does the company's effective tax rate compare with the prior year?
The effective tax rate for the quarter was 23.3%, up from 20.8%, and for the nine months it was 23.1%, up from 6.7%. The filing attributes the increase primarily to reduced excess tax benefits from equity compensation, since the prior-year period included stock option exercises by the Chief Executive Officer that did not recur in the current year.
06—Continue